KAM
INDV icon

Kazazian Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Kazazian Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,583
Closed -$202K – 50
2025
Q2 		$202K Sell
13,583
-65,842
-83% -$767K 0.28% 43
2025
Q1 		$630K Sell
79,425
-53,758
-40% -$565K 0.51% 28
2024
Q4 		$1.71M Buy
+133,183
New +$1.37M 1.3% 20

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Kazazian Asset Management's INDV Position: Q3 2025 in Review

Kazazian Asset Management sold out of Indivior Pharmaceuticals (INDV) in Q3 2025, closing a stake of 13,583 shares — an estimated $202K sold.

Kazazian Asset Management first reported a position in INDV in Q4 2024 and held it in 3 quarters. The position peaked at $1.71M in Q4 2024. 198 funds tracked by Wall St. Rank hold INDV as of Q3 2025.

  • Kazazian Asset Management reported no remaining Indivior Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Kazazian Asset Management sold 13,583 Indivior Pharmaceuticals shares in Q3 2025, an estimated $202K.
  • Kazazian Asset Management first reported a position in Indivior Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Kazazian Asset Management's Indivior Pharmaceuticals position peaked at $1.71M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2025.

Based on Kazazian Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.